聚焦超声神经调控:探索重度阿片类使用障碍的新型治疗
这项前瞻性开放标签单臂研究纳入8例重度原发性阿片类使用障碍并共病其他物质使用障碍的参与者,接受20分钟低强度聚焦超声(220 kHz)靶向双侧伏隔核调控,随访90天。结果显示无线索相关严重不良事件或影像异常,线索诱发的阿片渴求立即且持续降低(90天平均降低91%),尿液毒理学证实阿片及共病物质使用减少,静息态功能磁共振显示伏隔核与奖赏及认知区域连接减弱。作者认为伏隔核聚焦超声神经调控安全,可能是减少药物渴求与使用的辅助治疗,但需更大样本的假对照随机研究。
要点
- 8例重度阿片类使用障碍参与者接受双侧伏隔核低强度聚焦超声(220 kHz)20分钟调控,随访90天。
- 无线索相关严重不良事件或影像异常;线索诱发阿片渴求评分中位数从6.9(治疗前)降至0.6(90天)。
- 7例在30天时保持戒断,5例在整个90天随访期间保持戒断;作者认为需更大样本假对照随机研究。
核心结论
- 伏隔核聚焦超声神经调控安全,可能是减少重度阿片类及共病物质使用障碍个体药物渴求与使用的辅助治疗。
- 作者认为需要更大样本的假对照随机研究。
研究设计与样本
- 前瞻性、开放标签、单臂研究,纳入8例重度原发性阿片类使用障碍并共病其他物质使用障碍的参与者。
- 参与者接受20分钟低强度聚焦超声(220 kHz)神经调控,靶向双侧伏隔核,随访90天。
- 评估指标包括不良事件、物质渴求、物质使用(自我报告、尿液毒理学)、情绪、神经系统检查及解剖和功能磁共振成像,于聚焦超声后1、7、30、60、90天进行。
主要发现
- 未观察到设备相关的严重不良事件或影像学异常。
- 聚焦超声后线索诱发的阿片渴求立即(p < .002)且持续(p < .0001;平均91%)降低,0至10分量表中位评分:治疗前6.9 vs 90天随访时0.6。
- 其他非法物质的渴求降低程度相似,例如甲基苯丙胺(p < .002)、可卡因(p < .02)。
- 尿液毒理学证实阿片及共病物质使用减少;7例在30天时保持戒断,5例在整个90天随访期间保持戒断。
- 静息态功能磁共振显示聚焦超声后伏隔核至奖赏和认知区域的连接减弱。
临床怎么用
- 作者认为伏隔核聚焦超声神经调控安全,可能是减少重度阿片类及共病物质使用障碍个体药物渴求与使用的辅助治疗。
- 作者认为需要更大样本的假对照随机研究。
局限性
- 作者认为需要更大样本的假对照随机研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Opioid use disorder remains a critical health care challenge because current therapeutic strategies have limitations that result in high recurrence and deaths. We evaluated the safety and feasibility of focused ultrasound (FUS) neuromodulation to reduce substance cravings and use in severe opioid and co-occurring substance use disorders. METHODS: This prospective, open-label, single-arm study enrolled 8 participants with severe, primary opioid use disorder with co-occurring substance use. Participants received a 20-minute session of low-intensity FUS (220 kHz) neuromodulation targeting the bilateral nucleus accumbens (NAc) with follow-up for 90 days. Outcome measures included safety, tolerability, feasibility, and effects of FUS neuromodulation by assessment of adverse events, substance craving, substance use (self-report, urine toxicology), mood, neurological examinations, and anatomical and functional magnetic resonance imaging (fMRI) at 1, 7, 30, 60, and 90 days post-FUS. RESULTS: No serious device-related adverse events or imaging abnormalities were observed. Following FUS, participants demonstrated immediate (p < .002) and sustained (p < .0001; mean 91%) reductions in cue-induced opioid craving, with median ratings on a scale from 0 to 10 as follows: 6.9 (pre-FUS) versus 0.6 (90-day post-FUS). Craving reductions were similar for other illicit substances (e.g., methamphetamine [p < .002], cocaine [p < .02]). Decreases in opioid and co-occurring substance use were confirmed by urine toxicology. Seven participants remained abstinent at 30 days; 5 participants remained abstinent throughout 90 days post-FUS. Resting-state fMRI demonstrated decreased connectivity from the NAc to reward and cognitive regions post-FUS. CONCLUSIONS: NAc FUS neuromodulation is safe and a potential adjunctive treatment for reducing drug cravings and use in individuals with severe opioid and co-occurring substance use disorders. Larger, sham-controlled, randomized studies are warranted.
引用
- Rezai A, Thompson-Lake DGY, D'Haese PF, et al. Focused Ultrasound Neuromodulation: Exploring a Novel Treatment for Severe Opioid Use Disorder. Biol Psychiatry. 2025. PMID: 39798597. doi:10.1016/j.biopsych.2025.01.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。